AI-generated illustration; not a photograph of the reported event.
- calendar_today November 7, 2026
Breakthrough for Pancreatic Cancer Patients in Columbus
Patients battling advanced pancreatic cancer at the John B. Amos Cancer Center in Columbus, Georgia, are experiencing newfound hope thanks to a newly FDA-approved treatment. The treatment, called Rasonque, is now available at the center and is designed to slow the growth of certain pancreatic tumors, giving patients valuable additional time.
A Deadly Cancer With Limited Early Symptoms
Pancreatic cancer has long been recognized as one of the deadliest forms of cancer, particularly because it often goes undetected until it reaches an advanced stage. Dr. Deepti Kantamani, a hematologist and oncologist at the John B. Amos Cancer Center, notes that the disease can develop silently over many years. "Pancreatic cancer, you know, doesn’t come overnight. It takes about 15 years, from forming a malignant cell to death," she explains.
Rasonque: A New Option Against Tumor Growth
Traditional treatments for pancreatic cancer—such as surgery, chemotherapy, and radiation—may not always be effective for every patient. For individuals seeking alternative solutions, Rasonque provides a targeted approach. The daily pill is specifically designed to block a mutation called RAS, which can drive the progression of pancreatic tumors.
Amber Keeton, Pharmacy Operations Manager at the John B. Amos Cancer Center, explained, "It’s a Ras inhibitor, which is a very common mutation in pancreatic cancer. And so it tells the cancer cells, basically, we’re going to turn your switch that stuck on. We’re going to turn it off." Keeton emphasized that some patients are experiencing significant improvements with the treatment.
Patient Stories: Measurable Results and Renewed Optimism
Ted Metcalfe, a retired auto parts store worker from Columbus, was diagnosed with pancreatic cancer in early 2026 after dealing with months of severe pain. Initially discouraged after his first round of standard treatment, Metcalfe is now among more than two dozen local patients receiving Rasonque.
Metcalfe shared measurable results from his treatment: "I started out at 205, and it’s down to 40. That’s a vast improvement," he said, referring to the drop in his tumor marker levels. This progress has not only improved his health outlook but also brought a sense of gratitude and hope for the future.
Clinical Trials and FDA Approval
Rasonque's path to FDA approval included a significant clinical trial. The trial showed that patients taking the medication had a median survival of about 13 months—almost double that of those on standard therapy. While experts stress that Rasonque is not a cure for pancreatic cancer, they highlight the importance of extended survival time, especially for those fighting advanced disease.
Access and Support for Patients
Patients who are prescribed Rasonque at the John B. Amos Cancer Center can also obtain their specialty medication through the Regional Hope Pharmacy, conveniently located within the cancer center. This allows for an integrated approach to treatment and ongoing support for patients and families facing the challenges of pancreatic cancer.
Doctors and staff at the center believe that this newly available option is not just another treatment—it is a meaningful step forward, giving cancer patients a reason to hold onto hope for more time and improved quality of life.
Source: wrbl.com.
